Biotech company Lentitek has secured £700,000 from Equity Gap, the Scottish angel syndicate, to accelerate its next-generation cancer treatments.
It brings total investment in the Edinburgh business to £1 million in the last six months, following a £300,000 Innovate UK grant.
Equity Gap helped pull together those committed to advancing its technology towards commercialisation. Funding was also provided by existing investors, including Gabriel-IS, Apollo Informal Investment, Scottish Enterprise, as well as prominent private investors.
Read more HERE.
